Michael Sumner

Since joining the Pharmaceutical Industry almost 20 years ago, Mike has held numerous Medical Affairs & Clinical Development positions both in Europe and the United States at Novartis Pharmaceuticals; Aventis Behring (now CSL Behring); Novo Nordisk and Shire. He is currently the Chief Medical Officer at Orexo US, Inc.

During his career, he has global experience in the area of wound healing clinical development having worked with Apligraf during his time at Novartis UK and most recently in the role of Vice President Clinical Development and Medical Affairs at Shire Regenerative Medicine where he was responsible for both Dermagraft development and medical support.

Prior to joining the Pharmaceutical Industry he earned his medical degree from The Royal London Hospital Medical School part of the University of London, practiced internal medicine and subsequently became a Member of the Royal College of Physicians.